The lawsuit escalates an unusual, high-profile battle between two large pharmaceutical companies over ownership of a coveted ...

The drug, which Lilly in-licensed four years ago and is designed to inhibit a protein known as P2X7, did not meet the company ...

A study volunteer receiving Intellia’s transthyretin amyloidosis treatment was hospitalized due to severe signs of liver ...

A 46% premium paid for RNA candidates reflects what the pharma giant has sought to do for the last few years: aim at ...

The startup, which has a pair of medicines in testing and others in development, aims to build the “ultimate coagulation ...

With $80 million in funding from a list of high-profile backers, the startup is developing bifunctional antibodies that drag ...

The company intends to meet with the FDA to discuss results that showed a level of improvement on a marker of muscle ...

The results could help expand use of Welireg, one of the medicines Merck is counting on to drive revenue growth when its ...

Leaders and decision-makers facing the task of bringing new facilities online need construction partners who understand these ...

Some on Wall Street weren’t too impressed with results from a pivotal trial that tested an Exelixis drug, zanzalintinib, in combination with Tecentriq.

Analysts called the proposed purchase of Avadel Pharmaceuticals a “clear” strategic fit for Alkermes, handing it an already marketed product for excessive daytime sleepiness.

Alnylam and Neurocrine shares tumbled despite upbeat sales reports. Elsewhere, Biogen is dealing with what one analyst called ...